Rebuttal From Dr Thursfield et al

Affiliations

¹ Alder Hey Children's NHS Foundation Trust, Liverpool, England.
² Barts Health NHS Trust, London, England.
³ National Heart and Lung Institute, Imperial College London, London, England; Royal Brompton and Harefield NHS Foundation Trust, London, England. Electronic address: j.c.davies@imperial.ac.uk.

Editorial

Rebecca M Thursfield et al. Chest. 2022 Jan.

. 2022 Jan;161(1):25.

doi: 10.1016/j.chest.2021.03.073.

¹ Alder Hey Children's NHS Foundation Trust, Liverpool, England.
² Barts Health NHS Trust, London, England.
³ National Heart and Lung Institute, Imperial College London, London, England; Royal Brompton and Harefield NHS Foundation Trust, London, England. Electronic address: j.c.davies@imperial.ac.uk.

No abstract available

Comment on

POINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? Yes.
Downey DG. Downey DG. Chest. 2022 Jan;161(1):18-20. doi: 10.1016/j.chest.2021.05.070. Chest. 2022. PMID: 35000701 No abstract available.
COUNTERPOINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No.
Thursfield RM, Shafi N, Davies JC. Thursfield RM, et al. Chest. 2022 Jan;161(1):21-24. doi: 10.1016/j.chest.2021.06.018. Chest. 2022. PMID: 35000702 No abstract available.
Rebuttal From Dr Downey.
Downey DG. Downey DG. Chest. 2022 Jan;161(1):24. doi: 10.1016/j.chest.2021.06.019. Chest. 2022. PMID: 35000703 No abstract available.